Diaceutics announces world’s first Diagnostic Network for Precision Medicine following $28m investment
Summary
DXRX addresses stakeholder collaboration problems which have led to a suboptimal testing ecosystem and has resulted in most precision medicines reaching only 50% of eligible patients in oncology1. It will significantly enhance Diaceutics’ service offering and enable it to meet the increased market demand being created by 1,0002 new precision medicines currently in pharmaceutical company pipelines. DXRX enables these laboratories to be integrated into a network providing a global flow of testing data, thus placing those labs at the center of precision medicine. The need for stakeholder collaboration has been addressed by building alliances with industry leading service providers in areas such as pathology training, health economics, reference standards, EQA and digital enablement. Diaceutics’ Chief Innovation Officer, Ryan Keeling, commented, “Given the richness of the data we have, Diaceutics has been uniquely positioned to identify that, as an industry, we have been getting it wrong when it comes to patient testing for precision medicines.
Classifications
AskAI Classifications
LabelsLinked Companies
